PMID- 9042557
OWN - NLM
STAT- MEDLINE
DCOM- 19970430
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 52 Suppl 7
DP  - 1996
TI  - Comparison of the efficacy and safety of low molecular weight heparins and 
      unfractionated heparin in the initial treatment of deep venous thrombosis. An 
      updated meta-analysis.
PG  - 30-7
AB  - The aim of this study was to determine whether treatment with low molecular 
      weight heparin (LMWH) reduces the incidence of recurrent thromboembolic events, 
      death, haemorrhages, and extension of thrombus more than treatment with 
      unfractionated heparin (UFH) in patients with established deep vein thrombosis 
      (DVT). The study design was an updated meta-analysis of results from 20 
      randomised controlled clinical studies comparing LMWH with UFH. The main outcomes 
      measured included i) the incidence of thromboembolic events (DVT and/or pulmonary 
      embolism): ii) the incidence of major haemorrhages; iii) total mortality; and iv) 
      extension of thrombus. Statistically significant reductions in favour of LMWH 
      were observed for mortality [common odds ratio (OR) 0.70, 95% confidence interval 
      (CI) 0.50 to 0.98; p = 0.035]. major haemorrhage (common OR 0.59, 95% CI 0.35 to 
      0.98; p = 0.042) and thrombus extension (common OR 0.65, 95% CI 0.44 to 0.96; p = 
      0.03). A nonsignificant trend, also in favour of LMWH, was observed for the 
      recurrence of venous thromboembolic events (common OR 0.77, 95% CI 0.55 to 1.08; 
      p = 0.13). The results from the meta-analysis showed that LMWHs seem to have a 
      higher benefit/risk ratio than UFH in the treatment of venous thrombosis.
FAU - Leizorovicz, A
AU  - Leizorovicz A
AD  - Clinical Pharmacology Department, Hopitaux de Lyon, France.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Thromboembolism/*prevention & control
MH  - Thrombophlebitis/*drug therapy
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.2165/00003495-199600527-00006 [doi]
PST - ppublish
SO  - Drugs. 1996;52 Suppl 7:30-7. doi: 10.2165/00003495-199600527-00006.